IDEXX Laboratories, Inc. $IDXX Shares Bought by CHICAGO TRUST Co NA

CHICAGO TRUST Co NA grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 61.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,793 shares of the company’s stock after purchasing an additional 2,205 shares during the period. CHICAGO TRUST Co NA’s holdings in IDEXX Laboratories were worth $3,255,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in IDXX. SHP Wealth Management purchased a new position in shares of IDEXX Laboratories during the 4th quarter valued at approximately $26,000. Virtus Advisers LLC purchased a new stake in IDEXX Laboratories during the third quarter worth $26,000. Park Place Capital Corp acquired a new stake in IDEXX Laboratories during the fourth quarter valued at $29,000. WealthCollab LLC acquired a new stake in IDEXX Laboratories during the second quarter valued at $30,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in IDEXX Laboratories in the third quarter valued at $36,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Citigroup started coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. UBS Group reduced their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Stifel Nicolaus lowered their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Finally, Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, June 25th. Seven research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Stock Up 2.1%

IDXX stock opened at $537.58 on Thursday. The stock has a market capitalization of $42.40 billion, a P/E ratio of 39.59, a P/E/G ratio of 2.88 and a beta of 1.55. The firm has a 50-day simple moving average of $555.94 and a 200-day simple moving average of $610.55. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 52 week low of $506.91 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.